Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results
Get Alerts TBRA Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Monday, July 25 to discuss Phase 2b results for cenicriviroc in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Teleconference/Webcast Details
Listen via Internet: http://ir.tobiratx.com/
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Access code: 55407004
A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 55407004.
About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira’s pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.
Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.
©2016 Tobira Therapeutics, Inc. All Rights Reserved.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160724005051/en/
Tobira Investor & Media Contact:
Ian Clements, Ph.D., +1
650-351-5013
[email protected]
or
BrewLife
Media Contact:
Kelly Boothe, Ph.D., +1 415-946-1076
[email protected]
Source: Tobira Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northfield Bancorp, Inc. Announces First Quarter 2024 Results
- Elavon and FreedomPay to transform payments for hospitality and retail in Europe
- South Florida City Launches Groundbreaking Initiative to Reduce Gun Violence and Foster Peace
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!